Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
December 8, 2008
- Share of Generics Too Low: MOF Council
December 8, 2008
- 2 Drugs for CML, 2 Anti-HIV Drugs Recommended for Approval
December 8, 2008
- REGULATORY NEWS IN BRIEF
December 8, 2008
- NBI Opens Research Institute in Kobe
December 8, 2008
- JPMA to Support Researchers to Obtain iPS Cell-Related IP Rights
December 8, 2008
- Korosho to Press Large Hospitals to Settle Prices by Year-End
December 1, 2008
- Japan Needs NHI Pricing System That Encourages Innovation: Mr Kinoshita
December 1, 2008
- Advent of Wholesaler Behemoth Will Induce Power Shift
December 1, 2008
- REGULATORY NEWS IN BRIEF
December 1, 2008
- Matsumotokiyoshi to Provide Dispensing Services at 200 Stores
December 1, 2008
- JODA Introduces GL for Online Sales of OTC Drugs
December 1, 2008
- Asahi Kasei Obtains All Rights Related to Naftopidil from Roche Diagnostics
December 1, 2008
- Groups Present Petition Calling For Ban of Online Sales of Drugs
December 1, 2008
- EPS: CRO Business Props Up 19.2% Growth in Sales
December 1, 2008
- Final Draft GL Published for HRT
December 1, 2008
- BUSINESS NEWS IN BRIEF
December 1, 2008
- SELF-MEDICATION NEWS IN BRIEF
December 1, 2008
- Nichi-Iko to Overtake Taiyo to Become 2nd Largest Generic House, Following Sawai
December 1, 2008
- Pfizer to Perform Study in Japanese Patients to Strengthen Evidence for Selara
December 1, 2008
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…